Pure Global
NCT06410326

Mapping the Longitudinal, Multidimensional Impact of MS in Relation to Variables Indicative of Neurological Reserve

National MS Center Melsbroek·ClinicalTrials.govCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Sclerosis
Study type
Observational
Sponsor & location
Primary sponsor
National MS Center Melsbroek
Location
Melsbroek, Belgium
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Apr 01, 2024
Enrollment
2600 participants
Primary outcome

EDSS,Functional tests,Cognitive tests,The EQ-Visual Analog Score (EQ-VAS)

Summary

Some MS patients quickly accumulate neurological deficits, while others remain well for
 decades. Even though associations with age, sex, health behaviors, comorbidities and social
 determinants of health are widely acknowledged, the clinical heterogeneity in MS is poorly
 understood and variables with a robust prognostic value are lacking. Recent data suggest a
 key role for resilience in the central nervous system, potentially supporting the concept of
 neurological reserve in MS.

ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06410326
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06410326 through Pure Global AI's free database. This phase not specified trial is sponsored by National MS Center Melsbroek and is currently Completed. The study focuses on Multiple Sclerosis. Target enrollment is 2600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.